ES2120400T3 - Substitutos de la sangre a base de fluorocarburos. - Google Patents

Substitutos de la sangre a base de fluorocarburos.

Info

Publication number
ES2120400T3
ES2120400T3 ES87300248T ES87300248T ES2120400T3 ES 2120400 T3 ES2120400 T3 ES 2120400T3 ES 87300248 T ES87300248 T ES 87300248T ES 87300248 T ES87300248 T ES 87300248T ES 2120400 T3 ES2120400 T3 ES 2120400T3
Authority
ES
Spain
Prior art keywords
oxygen transport
fluorocarbures
substitutes
blood based
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87300248T
Other languages
English (en)
Inventor
David M Long Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alliance Pharmaceutical Corp
Original Assignee
Alliance Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alliance Pharmaceutical Corp filed Critical Alliance Pharmaceutical Corp
Application granted granted Critical
Publication of ES2120400T3 publication Critical patent/ES2120400T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)

Abstract

UNA EMULSION DE PERFLUOROCARBONO BROMADO NO TOXICA PARA USO INTERNO E INTRAVENOSO EN ANIMALES, INCLUYENDO HUMANOS, PARA USAR COMO MEDIO DE TRANSPORTE DE OXIGENO Y COMO MEDIO PARA AUMENTAR EL CONTRASTE DE TUMORES Y OTROS ELEMENTOS, ES ESTABLE CON CARACTERISTICAS DE TAMAÑO MUY PEQUEÑO PARA PERIODOS AMPLIOS EN EXCESO DE DIECIOCHO MESES Y DESPUES DE ESTERILIZACION, CON UN COMPONENTE DE ESTABILIZACION SELECCIONADO DE HORMONAS ESTEROIDES, TOCOFEROLES, COLESTEROLES Y SUS COMBINACIONES. UN COMPONENTE ANTIOXIDANTE MEJORA LA DISTRIBUCION EN EL TRANSPORTE DE OXIGENO.
ES87300248T 1986-01-14 1987-01-13 Substitutos de la sangre a base de fluorocarburos. Expired - Lifetime ES2120400T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/818,690 US4865836A (en) 1986-01-14 1986-01-14 Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
CA000604769A CA1338854C (en) 1986-01-14 1989-07-05 Oxygenation of blood substitutes
AU39649/89A AU3964989A (en) 1986-01-14 1989-07-05 Oxygenation of blood substitutes

Publications (1)

Publication Number Publication Date
ES2120400T3 true ES2120400T3 (es) 1998-11-01

Family

ID=27153954

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87300248T Expired - Lifetime ES2120400T3 (es) 1986-01-14 1987-01-13 Substitutos de la sangre a base de fluorocarburos.

Country Status (12)

Country Link
US (1) US4865836A (es)
EP (1) EP0231070B1 (es)
AT (1) ATE167054T1 (es)
AU (3) AU599068B2 (es)
CA (2) CA1279011C (es)
DE (1) DE3752194T2 (es)
ES (1) ES2120400T3 (es)
HK (1) HK1011504A1 (es)
IE (1) IE81097B1 (es)
NO (1) NO173214C (es)
WO (1) WO1991000090A1 (es)
ZA (1) ZA87252B (es)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931472A (en) * 1985-09-17 1990-06-05 Biomed Technology, Inc. Fluorinated triethylenediamine as an oxygen transport agent
US4987154A (en) * 1986-01-14 1991-01-22 Alliance Pharmaceutical Corp. Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use
US5077036A (en) * 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
US5284645A (en) * 1987-08-05 1994-02-08 Alliance Pharmaceutical Corp. Fluorocarbon emulsions containing amino acid based anti-inflamatory agents and buffer systems
US5847009A (en) 1986-01-14 1998-12-08 Alliance Pharmaceutical Corp. Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions
US5219538A (en) * 1987-03-13 1993-06-15 Micro-Pak, Inc. Gas and oxygen carrying lipid vesicles
US5171755A (en) * 1988-04-29 1992-12-15 Hemagen/Pfc Emulsions of highly fluorinated organic compounds
US4951673A (en) * 1988-08-19 1990-08-28 Alliance Pharmaceutical Corp. Magnetic resonance imaging with perfluorocarbon hydrides
US5061688A (en) * 1988-08-19 1991-10-29 Illinois Institute Of Technology Hemoglobin multiple emulsion
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
US5116599A (en) * 1989-07-31 1992-05-26 Johns Hopkins Univ. Perfluoro-t-butyl-containing compounds for use in fluorine-19 nmr and/or mri
US5234680A (en) * 1989-07-31 1993-08-10 Johns Hopkins Univ. Perfluoro-t-butyl-containing compounds for use in fluorine-19 NMR and/or MRI
GB8919929D0 (en) * 1989-09-04 1989-10-18 Nycomed As Compositions
US20020150539A1 (en) 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5305757A (en) * 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5209720A (en) * 1989-12-22 1993-05-11 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes
US6001335A (en) * 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5922304A (en) * 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5228446A (en) * 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5149319A (en) * 1990-09-11 1992-09-22 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids
US5656211A (en) * 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5776429A (en) * 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US6146657A (en) * 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5236694A (en) * 1990-02-21 1993-08-17 The Board Of Regents, The University Of Texas System 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
US5196199A (en) * 1990-12-14 1993-03-23 Fuisz Technologies Ltd. Hydrophilic form of perfluoro compounds and method of manufacture
US6344489B1 (en) 1991-02-14 2002-02-05 Wayne State University Stabilized gas-enriched and gas-supersaturated liquids
US5874062A (en) * 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
FR2679150A1 (fr) * 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
AU2441592A (en) * 1991-08-08 1993-03-02 Leigh D. Segel Fluorocarbon blood substitute
US6723303B1 (en) 1991-09-17 2004-04-20 Amersham Health, As Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane
MX9205298A (es) * 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
WO1993005819A1 (en) * 1991-09-17 1993-04-01 Sonus Pharmaceuticals, Inc Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media
US5325860A (en) * 1991-11-08 1994-07-05 Mayo Foundation For Medical Education And Research Ultrasonic and interventional catheter and method
US5264220A (en) * 1991-11-12 1993-11-23 Long David M Jr Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents
US5403575A (en) * 1991-12-12 1995-04-04 Hemagen/Pfc Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of using them
US5344393A (en) * 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US5380752A (en) * 1992-05-01 1995-01-10 Monte; Woodrow C. Method for preventing oxidation of crystalline steroid alcohols in cells, lipoproteins, and chylomicrons
EP0804944A3 (en) * 1992-05-04 1998-08-26 UNGER, Evan C A method of providing a gas composition in a biological tissue or fluid in vivo
US5295953A (en) * 1992-05-26 1994-03-22 Hemagen/Pfc Method and apparatus for extracorporeal separation of fluorochemicals from whole blood of a patient
US5350359A (en) * 1992-07-16 1994-09-27 Temple University Of The Commonwealth System Of Higher Education Control, treatment and/or diagnosis of physiological conditions with degassed perfluorocarbon liquid
US5628930A (en) * 1992-10-27 1997-05-13 Alliance Pharmaceutical Corp. Stabilization of fluorocarbon emulsions
US5595687A (en) * 1992-10-30 1997-01-21 Thomas Jefferson University Emulsion stability
IL108416A (en) 1993-01-25 1998-10-30 Sonus Pharma Inc Colloids with phase difference as contrast ultrasound agents
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
HUT72323A (en) * 1993-01-25 1996-04-29 Sonus Pharma Inc Phase shift colloids as ultrasound contrast agents
AU6365894A (en) * 1993-03-16 1994-10-11 Alliance Pharmaceutical Corporation Fluorocarbon compositions containing a visible or fluorescent label
US5635538A (en) * 1993-03-16 1997-06-03 Alliance Pharmaceutical Corp. Fluorocarbon emulsions with reduced pulmonary gas-trapping properties
US5470885A (en) * 1993-09-29 1995-11-28 The Research Foundation Of The State University Of New York Fluorocarbons as anti-inflammatory agents
US5969004A (en) * 1993-10-15 1999-10-19 The Gillette Company Aqueous inks
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5502094A (en) * 1994-05-20 1996-03-26 Minnesota Mining And Manufacturing Company Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use
US5658962A (en) 1994-05-20 1997-08-19 Minnesota Mining And Manufacturing Company Omega-hydrofluoroalkyl ethers, precursor carboxylic acids and derivatives thereof, and their preparation and application
US5736121A (en) * 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5590651A (en) * 1995-01-17 1997-01-07 Temple University - Of The Commonwealth System Of Higher Education Breathable liquid elimination analysis
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5997898A (en) * 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US5741248A (en) * 1995-06-07 1998-04-21 Temple University-Of The Commonwealth System Of Higher Education Fluorochemical liquid augmented cryosurgery
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US5726209A (en) * 1995-06-07 1998-03-10 Alliance Pharmaceutical Corp. Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir
US5897851A (en) * 1995-06-07 1999-04-27 Sonus Pharmaceuticals, Inc. Nucleation and activation of a liquid-in-liquid emulsion for use in ultrasound imaging
US5865784A (en) 1995-06-07 1999-02-02 Alliance Pharmaceutical Corp. Method of hemodilution facilitated by monitoring oxygenation status
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
WO1997025978A1 (fr) * 1996-01-15 1997-07-24 BELOYARTSEV, Arkady Felixovich Procede de production d'emulsions perfluorocarbonees a des fins medicales
US5611344A (en) * 1996-03-05 1997-03-18 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
AU721209B2 (en) * 1996-03-05 2000-06-29 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
US5861175A (en) 1996-03-15 1999-01-19 Alliance Pharmaceutical Corp. Use of fluorocarbons for diagnosis and treatment of articular disorders
WO1997040679A1 (en) * 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5843024A (en) 1996-05-17 1998-12-01 Breonics, Inc. Solution and process for resuscitation and preparation of ischemically damaged tissue
US5837221A (en) * 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
JP4139440B2 (ja) * 1996-09-11 2008-08-27 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 造影剤及び血管拡張薬を用いる画像診断のための改良された方法
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US6026815A (en) * 1996-10-10 2000-02-22 Gholam A. Peyman Radiopaque liquid as radiation blocking agent
US5834519A (en) 1996-10-11 1998-11-10 Wayne State University Stabilized gas-supersaturated emulsions and suspensions
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US7452551B1 (en) 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
EP1365068B1 (en) * 2002-05-10 2008-05-07 The Procter & Gamble Company Embossed tissue having loosened surface fibers and method for its production
US7357937B2 (en) 2002-09-24 2008-04-15 Therox, Inc. Perfluorocarbon emulsions with non-fluorinated surfactants
US20050118108A1 (en) * 2003-11-28 2005-06-02 Cowan Ada S. Pulmonary delivery of a liquid medicament aerosol
US20050118124A1 (en) * 2003-12-01 2005-06-02 Reinhart Gale M. Compositions for treating keratinous surfaces
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
AP2008004645A0 (en) * 2006-03-14 2008-10-31 Sergey Ivanovich Vorobyev Perfluorocarbon gas transferring emulsion for medico-biological use, the composition and the production method thereof a medicinal agent
DE102007015598A1 (de) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
US20110130444A1 (en) * 2007-05-04 2011-06-02 Stefan Moisyadi Methods and compositions for targeted delivery of gene therapeutic vectors
US8440333B2 (en) * 2007-06-13 2013-05-14 Sony Corporation Fuel cell and electronic apparatus
US9351943B2 (en) * 2010-07-01 2016-05-31 Matthew T. McLeay Anti-fibroblastic fluorochemical emulsion therapies
WO2013165473A1 (en) 2012-05-01 2013-11-07 Therox, Inc. System and method for bubble-free gas-enrichment of flowing liquid within a conduit
WO2016134275A1 (en) 2015-02-20 2016-08-25 Bayer Healthcare Llc Contrast imaging agent with dissolved gas-evolving fluid
EP3458037A4 (en) 2016-05-16 2020-01-29 MTM Research, LLC TARGETED FLUOROCHEMICAL THERAPIES
WO2019079587A1 (en) * 2017-10-19 2019-04-25 Oakwood Healthcare, Inc. SYSTEM AND METHOD FOR PROVIDING CONTRAST AGENT

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3958014A (en) * 1970-09-05 1976-05-18 The Green Cross Corporation Process for preparing injection-purpose fluorocarbon emulsion capable of carrying oxygen
US3975512A (en) * 1970-12-21 1976-08-17 University Of Illinois Foundation Non-toxic brominated perfluorocarbons radiopaque agents
US3818229A (en) * 1970-12-21 1974-06-18 Univ Illinois Radiopaque agents comprising brominated perfluorocarbons
JPS5331209B2 (es) * 1973-10-05 1978-09-01
US4073879A (en) * 1974-08-26 1978-02-14 University Of Illinois Foundation Brominated perfluorocarbon radiopaque agents
US4105798A (en) * 1976-07-19 1978-08-08 Sun Ventures, Inc. Perfluoro polycyclic compounds for use as synthetic blood and perfusion media
US4146499A (en) * 1976-09-18 1979-03-27 Rosano Henri L Method for preparing microemulsions
US4232665A (en) * 1979-01-10 1980-11-11 Vaseen Vesper A Portable lung apparatus
ES240864Y (es) * 1979-01-19 1979-10-16 Dispositivo anti-contaminacion para su utilizacion en qui- rofanos.
DE3049665T1 (de) * 1979-06-25 1982-03-18 Suntech Use of perfluorocarbon as burn treatment
FR2515198A1 (fr) * 1981-10-22 1983-04-29 Centre Nat Rech Scient Microemulsions aqueuses de fluorocarbures indefiniment stables a une temperature donnee, procede d'obtention et application a titre de transporteurs d'oxygene
US4343797A (en) * 1981-01-05 1982-08-10 Ecanow Charles S Synthetic whole blood and a method of making the same
US4439424A (en) * 1981-01-05 1984-03-27 Neomed Inc. Synthetic whole blood
JPS5832829A (ja) * 1981-08-22 1983-02-25 Green Cross Corp:The 血管造影剤
US4450841A (en) * 1982-03-03 1984-05-29 Thomas Jefferson University Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
FR2523956A1 (fr) * 1982-03-26 1983-09-30 Ugine Kuhlmann Bis-(perfluoroalkyl)-1,2-ethenes ramifies, leur preparation et leur utilisation comme transporteurs d'oxygene convertisseur electromecanique
US4425334A (en) * 1982-04-02 1984-01-10 The Regents Of The University Of California Functional oxygen transport system
US4497829A (en) * 1982-07-27 1985-02-05 The University Of Pennsylvania Process for preparing perfluorochemical emulsion artificial blood
US4397870A (en) * 1982-07-27 1983-08-09 The University Of Pennsylvania Process for prolonging retention of emulsion particles in the bloodstream
US4423077A (en) * 1982-07-27 1983-12-27 The University Of Pennsylvania Perfluorochemical emulsion artificial blood
US4542147A (en) * 1982-08-07 1985-09-17 The Green Cross Corporation Perfluoro-1-azatricyclic amine compound
JPS59112936A (ja) * 1982-12-21 1984-06-29 Green Cross Corp:The ペルフルオロエ−テル化合物及びその製造法
US4640833A (en) * 1983-02-28 1987-02-03 Adamantech, Inc. Use of perfluorobromoalkyl ethers as X-ray contrast agents
JPS59166626A (ja) * 1983-03-09 1984-09-20 Kobe Steel Ltd 棒鋼の連続球状化熱処理方法
JPS60145153A (ja) * 1984-01-10 1985-07-31 三菱レイヨン株式会社 中空糸型人工肺
JPS60166626A (ja) * 1984-02-09 1985-08-29 Green Cross Corp:The 血管造影剤
EP0231091B1 (en) * 1986-01-24 1993-03-31 Children's Hospital Medical Center Stable emulsions of highly fluorinated organic compound
FR2619136B1 (fr) * 1987-08-07 1991-06-21 Maire Claude Plate-forme flottante, notamment pour des installations de loisirs
JPH0832829A (ja) * 1994-07-18 1996-02-02 Toshiba Corp 画面位置調整回路
JPH0946230A (ja) * 1995-07-27 1997-02-14 Yamaha Corp Ｄ／ａコンバータ
JP3596953B2 (ja) * 1995-08-30 2004-12-02 ポーラ化成工業株式会社 美白化粧料

Also Published As

Publication number Publication date
CA1338854C (en) 1997-01-21
WO1991000090A1 (en) 1991-01-10
NO173214C (no) 1993-11-17
ATE167054T1 (de) 1998-06-15
AU3964989A (en) 1991-01-17
AU608880B2 (en) 1991-04-18
AU2051488A (en) 1989-04-13
IE81097B1 (en) 2000-03-08
AU6751687A (en) 1987-07-16
AU599068B2 (en) 1990-07-12
HK1011504A1 (en) 1999-07-09
NO870130L (no) 1987-07-15
IE870092L (en) 1987-07-14
US4865836A (en) 1989-09-12
DE3752194D1 (de) 1998-07-16
NO173214B (no) 1993-08-09
EP0231070A3 (en) 1987-09-23
EP0231070A2 (en) 1987-08-05
CA1279011C (en) 1991-01-15
DE3752194T2 (de) 1999-01-14
NO870130D0 (no) 1987-01-13
EP0231070B1 (en) 1998-06-10
ZA87252B (en) 1987-11-25

Similar Documents

Publication Publication Date Title
ES2120400T3 (es) Substitutos de la sangre a base de fluorocarburos.
ATE150641T1 (de) Nagellack zur behandlung von onychomykosen
KR930703038A (ko) 증대된 약제 유량을 나타내는 아포화된 경피적 약제 전달장치
SE8803087L (sv) Ett nytt saett foer behandling av erektil dysfunktion
DE69230254T2 (de) Herstellung von Mikropartikeln
SE8304143D0 (sv) Perfluorokemisk emulsion for artificiellt blod
SE8304144L (sv) Forfarande for forlengning av uppehallstiden for emulsionspartiklar i blodomloppet
DE59006842D1 (de) Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung.
ES2023880T5 (es) Fijador para el cabello.
Rohrbach et al. Aggregate risk study of exposure to endophyte-infected (Acremonium coenophialum) tall fescue as a risk factor for laminitis in horses
Swank et al. Oxygen availability in brain tissues after lipid meals
Hawkins et al. Epiglottitis in horses: 20 cases (1988–1993)
Lee Microscopic observations on the action of histamine on small blood vessels
SE7703076L (sv) Vetskestabiliserad enzymreagentkomposition och sett for dess astadkommande
Rudzki et al. Dermatitis from retinoic acid.
Howard-Flanders et al. Tissue Oxygen Tension and Radiotherapy: A Review and Bibliography Based on a Conference in Burlington, Vermont, August 1958
DE3484329D1 (de) Verwendung von gamma-interferon zur herstellung eines wirkstoffes in der behandlung von lepra.
DK447488D0 (da) Forbedringer vedroerende anvendelsen af epidermal vaekstfaktor
Meier Prolactin volume 6. Effects and clinical significance: By David F. Horrobin. Eden Medical Research, St. Albans, Vermont. $18.00. 148 pp.; Subject index. 1978
Mehta et al. Critical Care Management of a Pigeon under Shock due to Electrocution
McLeish The homosexual.
Khatra et al. Age related changes in the capillary index of the caprine hypophysis cerebri
McEwen Psychoneuroendocrinology: Influence of Hormones on the Nervous System. Proceedings of a meeting, Brooklyn, NY, June 1970. DH Ford, Ed. Karger, Basel, 1971 (US distributor, Phiebig, White Plains, NY). xx, 504 pp., illus. $31.45.
Simcox On Being Both Christian and Religious
Kennedy Addenda to" The Close Friendship of Gabriel Téllez and Pérez de Montalván: Its Possible Significance for the'Segunda parte'of Tirso"

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 231070

Country of ref document: ES